Does ENZALUTAMIDE Cause Tumour marker increased? 9 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 9 reports of Tumour marker increased have been filed in association with ENZALUTAMIDE (Xtandi). This represents 0.0% of all adverse event reports for ENZALUTAMIDE.
9
Reports of Tumour marker increased with ENZALUTAMIDE
0.0%
of all ENZALUTAMIDE reports
0
Deaths
1
Hospitalizations
How Dangerous Is Tumour marker increased From ENZALUTAMIDE?
Of the 9 reports, 1 (11.1%) required hospitalization.
Is Tumour marker increased Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ENZALUTAMIDE. However, 9 reports have been filed with the FAERS database.
What Other Side Effects Does ENZALUTAMIDE Cause?
Fatigue (8,891)
Death (6,680)
Malignant neoplasm progression (4,696)
Prostatic specific antigen increased (3,731)
Asthenia (3,589)
Drug ineffective (3,468)
Hot flush (3,144)
Decreased appetite (3,069)
Nausea (2,898)
Dizziness (2,776)
What Other Drugs Cause Tumour marker increased?
PALBOCICLIB (817)
FULVESTRANT (408)
NIRAPARIB (356)
LETROZOLE (343)
RIBOCICLIB (317)
RUCAPARIB CAMSYLATE (257)
CAPECITABINE (228)
EVEROLIMUS (228)
ELACESTRANT (222)
OLAPARIB (171)
Which ENZALUTAMIDE Alternatives Have Lower Tumour marker increased Risk?
ENZALUTAMIDE vs EPCORITAMAB
ENZALUTAMIDE vs EPCORITAMAB-BYSP
ENZALUTAMIDE vs EPERISONE
ENZALUTAMIDE vs EPHEDRINE
ENZALUTAMIDE vs EPINASTINE